This invention relates to a compound of platinum having the structure: ##STR1## in which X and Y are halogenoid groups which are the same or different and are preferably both chloride but may be other halide or pseudohalide such as cyanate, thiocyanate and azide or other similar groups, and A and b are the same or different branched chain aliphatic amine groups co-ordinated to the Pt through their N atoms.
|
6. A composition comprising a co-ordination compound of platinum having the structures: ##STR5## in which X and Y are halogen and A and b are exo 2 amino norbornane.
1. A co-ordination compound of platinum having the structure: ##STR4## in which X and Y are halogen and A and b are the same or different branched chain aliphatic amine groups or C-substituted branched chain aliphatic amine groups co-ordinated to the Pt through their N atoms each having the general formula
Cn R2n+1 NH2 in which n may vary from 3 to 9 and in which all of the R groups are the same or different and are selected from the group consisting of hydrogen, alkyl, aryl, alkaryl, aralkyl, halogen, pseudohalogen, hydroxy, carbonyl, formyl, nitro, amido, amino, sulphonic acid, sulphonic acid salt, carboxylic acid and carboxylic acid salt. 2. A compound according to
3. A compound according to
4. A compound according to
5. A compound according to
7. The compound cis-dichloro-trans-dihydroxybis (isopropylamine) platinum IV hydrate.
8. A compound according to
|
|||||||||||||||||||||||||||
This invention relates to new compositions of matter containing platinum.
According to one aspect of the present invention a composition of matter comprises a co-ordination compound of platinum having the structure: ##STR2## in which X and Y are halogenoid groups which are the same or different and are preferably both chloride but may be other halide or pseudohalide such as cyanate, thiocyanate and azide and A and B are the same or different branched chain aliphatic amine groups co-ordinated to the Pt through their N atoms.
According to a second aspect of the present invention there is provided a co-ordination compound of platinum having the structure: ##STR3## in which X and Y are halogenoid groups which are the same or different and are preferably both chloride but may be other halide pseudohalide such as cyanide, cyanate, thiocyanate, or azide or other similar groups and A and B are the same or different branched chain aliphatic amine groups or C-substituted branched chain aliphatic amine groups co-ordinated to the Pt through their N atoms each having the general formula
Cn R2n+1 NH2
in which n may vary from 3 to 9 and in which all of the R groups are either the same or different and are preferably all hydrogen but may be selected from the group consisting of hydrogen, alkyl, aryl, alkaryl, aralkyl, halogen, pseudohalogen, hydroxy, carbonyl, formyl, nitro, amido, amino, sulphonic acid, sulphonic acid salt, carboxylic acid, carboxylic acid salt, and substituted alkyl, aryl, alkaryl and aralkyl groups.
The platinum is preferably present as Pt4+, thus producing a neutral complex with two hydroxyl and two halide ligands.
Although R groups other than hydrogen are not normally preferred, they may be used and may comprise lower alkyl such as methyl or ethyl or a solubilizing group such as a sulphonic acid group. Solubilizing groups as substituents such as carboxylic acid, sulphonic acid, carboxylic acid salt, sulphonic acid salt, e.g. the sodium, potassium or lithium salts are sometimes appropriate when the clinical conditions require high solubility.
Throughout the specification and claims, the term "halogenoid" is used to mean halide (chloride, bromide, iodide or fluoride) or pseudohalide such as cyanide, cyanate, thiocyanate or azide.
Suitable branched chain amine compounds which may be used for groups A and B are isopropylamine, isobutylamine, isoamylamine and 2-aminohexane.
Results obtained using trans di-hydroxo complexes of Pt(IV) where in the above formula X and Y are both chloride and A and B are the same stated branched chain amine are as follows:
| ______________________________________ |
| mgm./Kgm Therapeutic |
| Tumour A and B ID90 |
| LD50 |
| Index (II) |
| ______________________________________ |
| ADJ/PC6 exo 2 amino nor |
| 40.5 660 16.3 |
| bornane |
| ISO propylamine |
| 7.5 90 12.0 |
| (oil) |
| (water) 4.2 54 12.9 |
| ISO Butylamine |
| 19.5 410 21 |
| ISO pentylamine |
| 112 800 7.1 |
| (amylamine) 19.0 20 37.9 |
| ______________________________________ |
| ED90 |
| LD50 |
| TI |
| ______________________________________ |
| Walker ISO propylamine |
| (oil) 17 45 2.6 |
| (water) 16 56 3.5 |
| ______________________________________ |
These results were obtained using the standard test protocol for the ADJ/PC6 and Walker tumours on Balb-c white mice.
These series of results obtained using the standard test protocol for the P 388 (ascitic) lymphocytic leukaemia using the isopropylamine complex are as follows:
| ______________________________________ |
| % age |
| Control Animal Increase |
| Dose Body weight Tumour Control |
| in life |
| mgm/ weight difference |
| evaluation |
| (Days) span |
| Kgm change (T - C) Test (days) |
| (C) (T/C) |
| ______________________________________ |
| 200 -1.4 -4.6 6.2 15.5 |
| 100 -1.4 -4.0 6.4 15.5 |
| 50.0 -1.4 -3.6 24.0 15.5 154 |
| 25.0 -1.4 -1.6 23.3 15.5 150 |
| 12.5 -1.4 -1.8 21.3 15.5 137 |
| 200 1.0 -1.0 4.19 11.8 |
| 100 1.0 -6.4 6.1 11.8 |
| 50.0 1.0 -6.5 8.0 11.8 |
| 25.0 1.0 -5.7 15.0 11.8 127 |
| 12.5 1.0 -4.2 21.8 11.8 184 |
| 200 1.0 -1.0 3.0 11.8 |
| 100 1.0 -6.5 6.8 11.8 |
| 50.0 1.0 -5.2 18.0 11.8 152 |
| 25.0 1.0 -4.0 16.1 11.8 136 |
| 12.5 1.0 -2.5 15.3 11.8 129 |
| ______________________________________ |
Other branched chain amines which may be used as ligands A and B are:
2 amino 5 methylhexane
2 amine 4 methylhexane
2 amino heptane
tert. butylamine
Preferred methods of preparation of trans dihydroxo cis dichloro diamine Pt (IV) complexes (i.e. where A+B in the above defined structure are as follows:
The complexes are prepared by the general method of heating a slurry of the respective cis-diaminedichloroplatinum (II) complex with hydrogen peroxide solution as exemplified below.
Recrystallised cis- [Pt(i-C3 H7 NH2)2 Cl2 ] (26.8 g) was slurried in hot water (50 ml) and aqueous hydrogen peroxide (40% v/v, 100 ml) was added with stirring. The slurry was boiled for 0.5 hours until yellow in colour, chilled, filtered and the residue washed with water, etharal and air dried. The crude product (20 g) was recrystallised from water (285 ml) with hydrogen peroxide solution (15 ml) and dried in vacuo at 100°C for four hours.
Yield 10.5 g. 35%
| ______________________________________ |
| Elemental analysis |
| C H N O Cl |
| ______________________________________ |
| Calculated % |
| 16.5 5.1 6.4 11.- 16.3 |
| Found % 16.6 4.8 6.4 11.7 16.1 |
| ______________________________________ |
The hydroxyl stretching absorption (vo --H) occurs at 3515 m cm-1
Recrystallised cis- [Pt(C7 H15 NH2)2 Cl2 ] (15 g) was slurried in warm water (31 ml) and hydrogen peroxide solution (40% v/v,60 ml) was added with stirring. The slurry was boiled for ten minutes, chilled, filtered and the orange product washed with water and dried in vacuo.
Yield 7.4 g. 46%
| ______________________________________ |
| Elemental analysis |
| C H N O Cl |
| ______________________________________ |
| Calculated % |
| 31.7 6.8 5.3 6.0 13.4 |
| Found % 32.1 6.7 5.5 6.2 13.6 |
| ______________________________________ |
The hydroxyl stretching absorption (vo --H) occurs at 3340 mg cm-1.
Platinum (IV) complexes are more soluble than Platinum (IV) complexes are more soluble than platinum (II) complexes and, after solubilizing Pt(IV) may be used in the form of Pt(II). The branched chain amine complexes of Pt(IV) are also useful in catalyst preparation by impregnating supports with an aqueous solution of the complex. Alternatively, the solution may be based upon an organic medium. The complexes of the invention may also be used as catalysts in the hydrosilation of organic compounds so as to introduce a silica radical into an organic compound and as synthetic intermediate compounds.
Tobe, Martin L., Khokhar, Abdul R., Braddock, Peter D. M.
| Patent | Priority | Assignee | Title |
| 4658047, | Sep 27 1985 | The United States of America as represented by the Department of Health; UNITED STATES OF AMERICA, THE, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Method of preparing 1,2-diaminocyclohexane tetrachloro platinum (IV) isomers |
| Patent | Priority | Assignee | Title |
| 3892790, | |||
| 3904663, | |||
| GB1432562, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Feb 20 1980 | Rustenburg Platinum Mines Limited | (assignment on the face of the patent) | / |
| Date | Maintenance Fee Events |
| Date | Maintenance Schedule |
| Jun 15 1985 | 4 years fee payment window open |
| Dec 15 1985 | 6 months grace period start (w surcharge) |
| Jun 15 1986 | patent expiry (for year 4) |
| Jun 15 1988 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Jun 15 1989 | 8 years fee payment window open |
| Dec 15 1989 | 6 months grace period start (w surcharge) |
| Jun 15 1990 | patent expiry (for year 8) |
| Jun 15 1992 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Jun 15 1993 | 12 years fee payment window open |
| Dec 15 1993 | 6 months grace period start (w surcharge) |
| Jun 15 1994 | patent expiry (for year 12) |
| Jun 15 1996 | 2 years to revive unintentionally abandoned end. (for year 12) |